Mink Therapeutics Inc INKT

$8.02 -0.59 (-6.85%)

Valuation

Market cap
44,200,000
Revenue TTM
$0
Net income TTM
$-12,490,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
19,000
Avg volume
16,930
Day's range
$7.76 – $8.60
Shares out
5,134,000
Stochastic %K
8%
Beta
0.49
Analysts
Moderate Buy
Price target
$44.00

Price

Company profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical...

Show more

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
212 994 8250
Website
https://minktherapeutics.com
Address
149 Fifth Avenue, Suite 500, New York, United States

Latest news

Stocktwits

neversurrender2024 Nov 20, 5:59 PM
$AGEN $INKT hey looks like mz giggles is getting her brazilian wax job....inkt taking a beating ....
0 replies
weichsel1 Nov 18, 9:38 PM
$INKT except explanation for the further drop today? Any news? Or just market volatility?
1 replies
2_logs_higher Nov 14, 4:32 PM
$AGEN & $INKT fwiw,
1 replies
enkemm Nov 12, 7:03 PM
$INKT A final benefit from the designation is designated products may qualify for priority review (shortening the FDA's final review timeline) and rolling review, which allows companies to submit sections of their marketing application as they are completed. To apply for the designation, sponsors must submit an RMAT request either alongside a new Investigational New Drug (IND) application or as an amendment to an active IND. Once the request is received, the FDA reviews the application and notifies the sponsor within 60 calendar days whether the designation is granted. If management gets a Phase III trial registered before December 31, then applies for RMAT, we could have the approval by March 1, 2027. NICE.......................................... Page 3
1 replies
enkemm Nov 12, 6:56 PM
$INKT In addition, the therapy must be intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition. Finally, early clinical data must show that the therapy has the potential to address unmet medical needs for that condition. Unlike Breakthrough Therapy designation, RMAT does not require evidence proving the drug is a substantial improvement over existing treatments. The key benefits from a RMAT designation are that it provides all the benefits of the FDA's Fast Track and Breakthrough Therapy programs. Also, sponsors receive meetings with senior FDA managers to design efficient clinical trials, and developers can discuss using surrogate or intermediate endpoints to support accelerated approval, rather than waiting years for traditional long-term clinical outcomes. Additionally, there are flexible ways to satisfy post-approval study requirements, including using real-world evidence, patient registries, or electronic health records. Page 2
0 replies
enkemm Nov 12, 6:46 PM
$INKT OrientBeach: The fact that management wants to register a Phase III trial within the next 6 weeks, and wants to do so under an accelerated Regenerative Medicine Advanced Therapy (RMAT) designation means they think they have man absolute winner....a ball buster for ARDS. For those who may not know, Regenerative Medicine Advanced Therapy (RMAT) designation is an expedited program created by the U.S. Food and Drug Administration (FDA) to speed up the development and review of regenerative medicine products for serious conditions. To qualify for the designation, the product must be a regenerative medicine therapy, such as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or a combination product using them. Certain human gene therapies and genetically modified cells (like CAR T-cell therapies) also qualify if they produce a durable effect on cells or tissues. Page 1
0 replies
OrientBeach Nov 12, 5:43 PM
$INKT Q3 10-K page 17 ‘. . . and a proposed hierarchical endpoint of survival with VV-ECMO at Day 14, followed by all-cause mortality through Day 28. We plan to meet with FDA before YE ‘26 to discuss the proposed design could contribute to a registration-enabling PIII trial, and we intend to pursue Regenerative Medicine Advanced Therapy designation’ Holy Smokes Batman
0 replies
OrientBeach Nov 12, 5:17 PM
$INKT Update: ‘In the nine months ended September 30th, 2026 the company sold 313,478 shares in net proceeds of $4.4M. No shares were sold during the three months ended September 30, 2026’ Page 12 Q3 10-K
2 replies